The Market and Future Potential for Molecular Point of Care (mPOC), 2023

The Market and Future Potential for Molecular Point of Care (mPOC), 2023

This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from novel trend to significant contributor to the market. The instruments sold by Abbott, BioMérieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point of care testing and microbiology IVD.

Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.

Kalorama reports provide real-world analysis and model for relevant circumstances. As an example, analysts provide two different market perspectives. Near patient molecular testing using small instruments, and molecular point-of-care. Both markets are provided so the report can be useful for any business plans. As far as we know, Kalorama is the only market research resource providing this insight.

The data in The Market and Future Potential for Molecular Point of Care (POC), 2023 includes information on systems and competitor analysis, as well as data on the size and growth of the market:What are the mPOC market opportunities beyond COVID-19?What are the current systems on the market? Who’s winning?What’s the size of the Molecular Point of Care Market: 2022-2027Geographic Breakout of the Molecular Point of Care Market, 2021 (N. America, Europe, APAC, RoW)Segment Breakout of Molecular Point of Care Market, 2022 (Respiratory vs. Other)Respiratory Segment Breakout, 2022 (Flu, RSV, Strep, Other)Breakout of mPOC Respiratory, 2022 (%; Flu, Strep, RSV, Other)Near Patient Molecular IVD Market: 2022-2027Near Patient Molecular Market Share by Vendor, 2022Molecular Point of Care Market Share by Vendor, 2022Company ProfilesMany trends are covered in the report, including the role of COVID-19 testing, menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC, and other trends.

Companies covered in this report, in profiles and/or product tables and market developments discussion include:Abbott LaboratoriesAidian OyAkonni BiosystemsAnitoabinx health, inc.Biocartis NVBioGXbioMérieux SACepheidCredo BioscienceCue HealthCuretis NVCuriosity Diagnostics (Bio-Rad)DiaSorin S.p.ADomus DiagnosticsFluxergyGenMark DiagnosticsGenomadixGreiner Bio-One GmbHLEX DiagnosticsMeridian Bioscience, Inc.Mesa Biotech, Inc.MicroGEMMinute MolecularNanopathQIAGEN NVQuantuMDx GroupQuidel CorporationRocheRover DiagnosticsSekisui Diagnostics LLCT2 Biosystems